<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Moreno-Ruiz N</submitter><funding>Cancer Research UK</funding><funding>Medical Research Council</funding><funding>National Institute for Health Research (NIHR)</funding><funding>Wellcome Trust</funding><pagination>1439-1443</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9712436</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>30(12)</volume><pubmed_abstract>An important fraction of patients with rare disorders remains with no clear genetic diagnostic, even after whole-exome or whole-genome sequencing, posing a difficulty in giving adequate treatment and genetic counseling. The analysis of genomic data in rare disorders mostly considers the presence of single gene variants in coding regions that follow a concrete monogenic mode of inheritance. A digenic inheritance, with variants in two functionally-related genes in the same individual, is a plausible alternative that might explain the genetic basis of the disease in some cases. In this case, digenic disease combinations should be absent or underrepresented in healthy individuals. We develop a framework to evaluate the significance of digenic combinations and test its statistical power in diff</pubmed_abstract><journal>European journal of human genetics : EJHG</journal><pubmed_title>Assessing the digenic model in rare disorders using population sequencing data.</pubmed_title><pmcid>PMC9712436</pmcid><funding_grant_id>MR/M009203/1</funding_grant_id><funding_grant_id>MC_EX_MR/M009203/1</funding_grant_id><funding_grant_id>MC_PC_14089</funding_grant_id><funding_grant_id>NF-SI-0512-10113</funding_grant_id><funding_grant_id>NF-SI-0617-10154</funding_grant_id><pubmed_authors>Stevens HE</pubmed_authors><pubmed_authors>Savage K</pubmed_authors><pubmed_authors>Craig CEH</pubmed_authors><pubmed_authors>Fowler T</pubmed_authors><pubmed_authors>Chan GC</pubmed_authors><pubmed_authors>Williams E</pubmed_authors><pubmed_authors>Sultana R</pubmed_authors><pubmed_authors>Smith KR</pubmed_authors><pubmed_authors>Boissiere JM</pubmed_authors><pubmed_authors>Daugherty LC</pubmed_authors><pubmed_authors>Tregidgo C</pubmed_authors><pubmed_authors>Pullinger J</pubmed_authors><pubmed_authors>Lopez FJ</pubmed_authors><pubmed_authors>Walsh E</pubmed_authors><pubmed_authors>Maleady-Crowe F</pubmed_authors><pubmed_authors>Genomics England Research Consortium</pubmed_authors><pubmed_authors>Lahnstein L</pubmed_authors><pubmed_authors>Hubbard TJP</pubmed_authors><pubmed_authors>Arostegui JI</pubmed_authors><pubmed_authors>Watters SA</pubmed_authors><pubmed_authors>Welland MJ</pubmed_authors><pubmed_authors>Stuckey A</pubmed_authors><pubmed_authors>Elgar G</pubmed_authors><pubmed_authors>Holman JE</pubmed_authors><pubmed_authors>Sieghart A</pubmed_authors><pubmed_authors>Zarowiecki M</pubmed_authors><pubmed_authors>Caulfield MJ</pubmed_authors><pubmed_authors>Hamblin A</pubmed_authors><pubmed_authors>Mueller M</pubmed_authors><pubmed_authors>Orioli A</pubmed_authors><pubmed_authors>Laayouni H</pubmed_authors><pubmed_authors>Ambrose JC</pubmed_authors><pubmed_authors>Scott RH</pubmed_authors><pubmed_authors>Spooner W</pubmed_authors><pubmed_authors>McDonagh EM</pubmed_authors><pubmed_authors>Tucci A</pubmed_authors><pubmed_authors>Moutsianas L</pubmed_authors><pubmed_authors>Bleda M</pubmed_authors><pubmed_authors>Leigh SEA</pubmed_authors><pubmed_authors>Patch C</pubmed_authors><pubmed_authors>Thomas ERA</pubmed_authors><pubmed_authors>Brittain H</pubmed_authors><pubmed_authors>Jones LJ</pubmed_authors><pubmed_authors>Mason J</pubmed_authors><pubmed_authors>Arumugam P</pubmed_authors><pubmed_authors>Kasperaviciute D</pubmed_authors><pubmed_authors>Ryten M</pubmed_authors><pubmed_authors>Hackett JM</pubmed_authors><pubmed_authors>Riesgo-Ferreiro P</pubmed_authors><pubmed_authors>Henderson S</pubmed_authors><pubmed_authors>Casals F</pubmed_authors><pubmed_authors>Pereira MB</pubmed_authors><pubmed_authors>Rogers T</pubmed_authors><pubmed_authors>Boardman-Pretty F</pubmed_authors><pubmed_authors>Polychronopoulos D</pubmed_authors><pubmed_authors>Baple EL</pubmed_authors><pubmed_authors>Lawson K</pubmed_authors><pubmed_authors>Kayikci M</pubmed_authors><pubmed_authors>Halai D</pubmed_authors><pubmed_authors>Thompson SR</pubmed_authors><pubmed_authors>Ibanez K</pubmed_authors><pubmed_authors>Murugaesu N</pubmed_authors><pubmed_authors>Leong IUS</pubmed_authors><pubmed_authors>Kousathanas A</pubmed_authors><pubmed_authors>Smedley D</pubmed_authors><pubmed_authors>Witkowska K</pubmed_authors><pubmed_authors>Tanguy M</pubmed_authors><pubmed_authors>Furio-Tari P</pubmed_authors><pubmed_authors>Smith SC</pubmed_authors><pubmed_authors>Jackson R</pubmed_authors><pubmed_authors>Giess A</pubmed_authors><pubmed_authors>Rendon A</pubmed_authors><pubmed_authors>Moreno-Ruiz N</pubmed_authors><pubmed_authors>Sosinsky A</pubmed_authors><pubmed_authors>Foulger RE</pubmed_authors><pubmed_authors>Perez-Gil D</pubmed_authors><pubmed_authors>Need AC</pubmed_authors><pubmed_authors>Sawant K</pubmed_authors><pubmed_authors>Boustred CR</pubmed_authors><pubmed_authors>de Burca A</pubmed_authors><pubmed_authors>Lao O</pubmed_authors><pubmed_authors>Siddiq A</pubmed_authors><pubmed_authors>Odhams CA</pubmed_authors><pubmed_authors>Rahim T</pubmed_authors><pubmed_authors>Devereau A</pubmed_authors><pubmed_authors>Wood SM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Assessing the digenic model in rare disorders using population sequencing data.</name><description>An important fraction of patients with rare disorders remains with no clear genetic diagnostic, even after whole-exome or whole-genome sequencing, posing a difficulty in giving adequate treatment and genetic counseling. The analysis of genomic data in rare disorders mostly considers the presence of single gene variants in coding regions that follow a concrete monogenic mode of inheritance. A digenic inheritance, with variants in two functionally-related genes in the same individual, is a plausible alternative that might explain the genetic basis of the disease in some cases. In this case, digenic disease combinations should be absent or underrepresented in healthy individuals. We develop a framework to evaluate the significance of digenic combinations and test its statistical power in diff</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2025-04-18T16:56:12.578Z</modification><creation>2025-04-07T04:24:34.916Z</creation></dates><accession>S-EPMC9712436</accession><cross_references><pubmed>36192439</pubmed><doi>10.1038/s41431-022-01191-x</doi></cross_references></HashMap>